Clinical Trial Update: A Safety Study of LY2811376 Single Doses in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating a single dose of LY2811376 in healthy subjects, sponsored by Eli Lilly and Company, related to Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY2811376 (LY2811376)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED